a b s t r a c t A series of new 5,5-diphenylhydantoin derivatives with various amineealkyl terminal fragments at N1position were synthesized. Then a series of twenty-eight compounds with the same hydantoin scaffold were evaluated for their potency to combat bacterial MultiDrug Resistance (MDR). Intrinsic antibacterial activities were first evaluated. As these compounds showed no direct activity on bacteria, their influence on minimal inhibitory concentration (MIC) of nalidixic acid was tested in two strains of Enterobacter aerogenes: the reference-strain ATCC-13048 and the CM-64 strain which over-produces AcrAB-TolC efflux pump. The compounds showed moderate-or low-anti-MDR properties. According to SAR-studies, hit compounds containing 2-methoxyphenylpiperazine at N1-terminal fragment and methylcarboxyl acid one at N3-position of hydantoin have been identified for further microbiological studies and pharmacomodulations to develop efflux pump inhibitors.
Introduction
Multidrug resistant (MDR) bacteria are a serious health problem due to the associated failure of the therapy of infectious diseases [1, 2] . One of the most important and widespread MDR mechanism bases on bacterial efflux proteins that expel all antibiotic classes out of the cell [3, 4] . Gram-negative bacteria provide efficient active expulsion of antibiotic molecules across the membranes and periplasm using energy-potential of membrane [3e6] . They contribute in both natural insensitivity to antibiotics and high levels of antibiotics resistance by acquiring additional mechanisms. Efflux pumps have been proposed as a potential target in order to restore the activity of antibiotics that are expelled by efflux pumps [7] . In the group of MDR Gram-negative bacteria, Enterobacter aerogenes is one of the frequently described pathogens, responsible for various hospital-acquired infections [4, 8, 9] . In the case of E. aerogenes such as many Enterobacteriaceae involved in infectious diseases, tripartite efflux pump AcrAB-TolC is the main efflux system which can extrude a large variety of cytotoxic substances from the cell membrane directly into the medium [4, 10, 11] . According to the recent lines of evidence, three main strategies to circumvent the bacterial resistance mechanism are described to restore an efficient intracellular concentration of antibiotics: (1) By-passing efflux activity: improving the molecular design of old antibiotics to reduce their efflux; (2) direct action on the membrane barrier: increasing the permeability of the bacterial cell envelope and drug uptake; (3) Blocking the efflux ability of bacterial cell: altering pump function [12] . Concerning the third strategy, a search for new chemical compounds with efflux pump inhibitor (EPI) properties is a current topic in medicinal chemistry. Within the search for new EPIs, some chemical groups of active compounds were identified that contain ring-or chain amineealkyl fragments linked to various aromatic moieties. Structure analysis of some potent EPIs indicated that piperazine-(NMP, NBP, Fig. 1 ), primary amine-, or guanidine fragment (PAbN) is profitable for the activity (Fig. 1 ). Among others, compound PAbN, a derivative of arginine, is a wellknown efflux pump inhibitor used in various microbiological tests as a reference compound [7] .
Our previous studies were focused on various chemical modifications of hydantoin to give new GPCR-agents [13e15], compounds with antiarrhythmic-and/or anticonvulsant activity [16e19] as well as antibacterial agents with some syndrome to inhibit drug resistance in mycobacterial cells [20, 21] . Based on interesting structures and pharmacological properties of the 5-aromatic-hydantoin derivatives, we decided to test this chemical group for their potency to combat MDR. This work describes the first step of the studies focused on 5,5-diphenylhydantoin derivatives. The research was divided into two stages. In the first stage synthesis and microbiological tests were carried out for the first generation of hydantoin derivatives 1e11 including compounds with N3-alkyl-, ester-, acid-or free hydrogen as well as tertiary amine: phenylpiperazine terminal fragment at N1-position (Table 1 ). According to the first results obtained, further chemical modifications of the 5,5-diphenylhydantoin derivatives 1e11 were performed by an exchange of N1-phenylpiperazine terminal fragment into primary, secondary-or tertiary amines, including heterocyclic-or non-aromatic piperazines as well as triazabicyclodecene moiety ( Table 2 ). Syntheses of new compounds 12e28, microbiological tests using strains of E. aerogenes as well as structureeactivity relationship studies were investigated.
Chemistry
Synthetic pathways to obtain the new hydantoin derivatives, belonging to first (1e11) or second generation (12e28) are illustrated on the Schemes 1e4. Synthesis of starting hydantoins 30, 31 and 33e40 from 5,5-diphenylhydantoin (29) (Scheme 1) has been performed according to described literature procedures [13, 15, 16] . Alkylation of the imidazole ring at N3-position gave methyl (30), ester (31) or trityl (40) derivatives (Scheme 1), subsequently alkylated further, this time at N1-position, which allowed to obtain the intermediate bromides (33e40) with different number of methylene groups n ¼ 3, 4, 5, 6 and 8 as linkers.
The latter alkylation was performed in acetone with potassium carbonate as a base and benzyltriethylammonium chloride (TEBA) acting as a phase transfer catalyst. An excess (30e50%) of the adequate dibromoalkane allows avoiding dimerization, a result of two-bromide substitutions. Long-term stirring (90e120 h) at room temperature gave satisfactory results. These mild conditions seem to minimize side nucleophilic substitutions that were noted during the pilot-reactions with boiling temperature. Bromides 33e40 were the starting materials for a number of nucleophilic substitution reactions that allowed preparing the target compounds (Schemes 2, 3).
A series of phenylpiperazine derivatives (1e3, 5, 6, 9) were prepared using synthetic pathway described in Scheme 2. Phenylpiperazine derivative 1 was synthesized within two-step process. In the first step bromoalkyletrityl derivative of hydantoin 40 reacted with phenylpiperazine to give 41, which was next cleaved from trityl group in acidic conditions using of 90% trifluoroacetic acid (TFA) in methylene chloride to give 1. Phenylpiperazineehydantoin derivative with N3-carboxylic terminal fragment 9 was obtained by basic hydrolysis of ester 42, performed in aquaemethanol conditions. Synthesis of ethoxycarbonylpiperazine derivatives 16, 18e20 was performed as two-phase alkylation of commercial ethyl piperazine-1-carboxylate with N1-bromoalkylhydantoin derivatives 36e39 (Scheme 3). Compound 17, a 3-hydantoinacetic acid derivative, was synthesized from corresponding ester 16 by basic hydrolysis carried out in similar conditions to those used to obtain 9. In case of free-piperazine derivative 21, synthesis came up against difficulties due to presence of two amine groups in piperazine with equal sensitivity for alkylating agents. At first, a number of pilot-syntheses was performed to obtain free-piperazine derivatives by cleavage of ethoxycarbonyl group of compounds 16, 18e20. Deprotections in both, basic and acidic conditions, did not give the target compounds. In basic conditions, the protecting group was very stable even in case of long term heating with concentrated KOH (6 M). Similar observation was noted in case of acidic hydrolysis with various concentrations of HCl. Acidic deprotection with TFA damaged hydantoin ring giving undesirable products. The best result gave two-phase alkylation of "free" piperazine by use of bromoalkyl derivative 39. The reaction (Scheme 3) was performed in excess of piperazine (3 eq) allowed to obtain pure compound 21.
Substitution of bromides 35e39 with the secondary amine 1,5,7triazabicyclo[4.4.0]dec-5-ene as well as potassium phthalimide was performed in acetone at 50e60 C, in the presence of K 2 CO 3 and TBAB (Scheme 3). In the case of compounds 22e25, reflux conditions led after several hours to expected products of substitution with simultaneous hydrolysis of the ester group. In the case of 26e28, Gabriel method [22] for primary amines synthesis was applied. Intermediate phthalimides were treated with hydrazine monohydrate in anhydrous ethanol to give 26e28 obtained as free bases. Synthesis of hydantoin derivatives with branched propyl linker (4, 7, 10e15) is shown in Scheme 4. 5,5-diphenylhydantoin alkylated at 3 position with methyl-(30) or methyl acetate (31) reacted first with 2,3-epichlorhydrine [16] to obtain the corresponding epoxide intermediates, which were cleaved by secondary amines (Scheme 4) giving 2-hydroxypropylamine derivatives of hydantoin (4, 7, 12e15, 43). Compound 8 was obtained by basic hydrolysis of 43 [15] . Acylation of the hydroxyl group of compounds 4 and 7 with acetic anhydride (Scheme 4) yielded products 10b and 11b that were converted into corresponding hydrochlorides 10 and 11. Table 2 Generation II: 1-aminealkyl derivatives of 5,5-diphenylhydantoin 12e28. 
Results and discussion

Intrinsic anti-bacterial activity
Compounds 1e28 were evaluated in vitro for their antibacterial activity by determining the minimum inhibitory concentration (MIC) with resistant Gram-negative bacteria E. aerogenes. Two following strains of E. aerogenes were used: reference-strain, ATCC 13048 and the derivative strain CM-64, which over-produces the AcrAB-TolC efflux pump. Results are shown in Table 3 . Most of the tested compounds exhibited low intrinsic antibacterial activity except compound 9 (0.0625 mM). However, these results show an increase MIC for compounds 8 and 9 in CM-64 strain. This increase is probably due to the over-expressed efflux pump and therefore suggests that these compounds can be recognized and transported by AcrAB-TolC efflux pump. But the difference in activity between the two strains is less important than that of nalidixic acid. This suggests a lower affinity of hydantoin derivatives for the targeted efflux pumps. A similar range of susceptibility values was obtained for the two strains. Most of the hydantoins had a mean value of 1.25 mM. The low intrinsic antibacterial activity of these molecules allowed us to analyze their effect on the nalidixic acid susceptibility of the MDR strain CM-64.
Influence of hydantoins on nalidixic acid MIC
Efflux pump inhibitory properties were also evaluated in the two strains of E. aerogenes ATCC 13048 and CM-64. To study the possible synergistic activity, the potential inhibitors were added during incubation with nalidixic acid that has been well described as efflux pump substrate [3, 6, 7] . PAbN (MIC ¼ 5 mM on ATCC 13048 and CM-64 strains) was used as a reference EPI according to previous studies [23] at the concentration of 50 mM. The first generation of compounds 1e11 was tested in the concentration range 62.5e333 mM (Fig. 2) according to the intrinsic antibacterial activity of each compound. Compounds of second generation 12e28 were tested in the concentration corresponding to the best first generation chemosensitizers (62.5 mM) to facilitate comparison. Anti-MDR activities of the compounds were expressed by activity gain A on nalidixic acid susceptibility, calculated as MIC of nalidixic acid, evaluated in absence of compound, divided by the MIC of the antibiotic in presence of the tested compound (Fig. 2) .
Generally, the compounds showed moderate or weak potentiating properties, significantly lower than those obtained for strong reference efflux pump inhibitor, PAbN. The most active compounds 8 and 9 showed significant 4-fold decrease of MIC of nalidixic acid in MDR strain CM-64 and 2-fold MIC-decrease in reference-strain (ATCC 13048) at the lowest dose of 62.5 mM (Fig. 2a ). All compounds tested at 100 mM (1e6 and 10) had no effect on MIC of nalidixic acid in the reference-strain. In this group, compounds 2 and 6 were the most active against MDR causing 4-fold-decrease of MIC of the antibiotic in the strain, which over-expresses AcrAB-TolC (Fig. 2b) . In case of compound 7, a decrease of MIC of nalidixic acid (4-fold, CM-64) was observed at higher concentration of 333 mM. Compounds 12e28, investigated at 62.5 mM, did not significantly influence MIC of nalidixic acid neither in ATCC 13048 reference-strain nor in CM-64 one.
Structureeactivity relationships
Although the tested hydantoin derivatives did not show high chemosensitizing potency, results allowed identify some structural properties profitable for the EPI activity targeted. In the first generation of hydantoin derivatives 1e11, 5,5-diphenyhydantoin as well as N1-phenylpiperazine terminated fragments are fixed structural properties for all investigated compounds. Chemical modifications were performed for substituents in N3-position and for alkyl linker between N1 and piperazine. Furthermore, modifications including electro-donor substituents at phenylpiperazine ring were investigated. The most promising compounds 8 and 9 decreased MIC of nalidixic acid in strains with over-production of AcrAB-TolC but did not influence the MIC in reference-strains. These derivatives possess N3-carboxylic terminal fragment and 2-methoxyphenylpiperazine functional group in N1 position. They differ only within length and properties of alkyl linker between hydantoin and piperazine. As these differences are minor (n ¼ 1 or 2, presence or not of hydroxyl group), it does not seem to affect activity. Other compounds with 2-methoxyphenylpiperazine fragment did not potentiate antibiotic activity in CM-64 or decrease nalidixic acid MIC at higher concentrations (Fig. 2) . Comparing structures of the generation 1 compounds, the main difference is shown in case of N3-substituent. Compounds with N3eH (1) and N3-ester fragment (5e7 and 11) showed various activities. The compounds displayed chemosensitizing activity lower than that of compounds possessing carboxylic group (8, 9) . The best of them decreased MIC of nalidixic acid at higher doses: 100 mM (6) and 333 mM (7) . Basing on this observation, the substituent CH 2 COOH at N3 seems to be a structural factor improving potentiating-properties. The influence of N3substituents on decrease of MIC of nalidixic acid in CM-64 is as follows:
Results obtained for first generation 1e11 revealed two most promising chemosensitizers (8 and 9), which contain methylcarboxylic acid N3-substituent, and 2-methoxyphenylpiperazine. The role of these two fragments was investigated in the next studies of the second generation of hydantoin derivatives (12e28). In this context, phenyl ring of phenylpiperazine moiety was replaced by 2-furoyl (12), 2-pyridil- (13, 14) , ethoxycarbonyl (16e20) or free hydrogen (21) as well as phenylpiperazine was exchanged into primary amine (26e28), isopropylamine (15) or triazabicyclodecene fragment (22e25) in order to understand the impact of the change of pharmacophore features. This new generation of compounds possesses either N3-carboxylic terminal fragment (17, 22e28) or the corresponding methyl ester (14e16, 18e21) ( Table 2) . Results demonstrated that no compound of the second generation (12e28) had better chemosensitizing-properties than that of compounds 8 and 9 but some structureeactivity relationship conclusions can be done. This second part of the study confirms the importance of the 2methoxyphenyl substituent of piperazine. Its replacement by non-aromatic functional group or an aromatic ring with a weaker electronic density as pyridyl one led to decrease of activity gain. Moreover, the nature of the amine group seems also to be important. Indeed, the replacement of piperazine by primary amine or triazabicyclodecene groups which have stronger basic properties decrease activity gain of the chemosensitizers. Higher basic properties lead to higher ionization of molecules, which could affect either the interaction with the putative target of chemosensitizers and/or the crossing through bacterial membranes.
Conclusion
The chemosensitizing activity of 28 5,5-diphenylhydantoin derivatives were evaluated in MDR bacterial cells which overproduce AcrAB-TolC efflux pump in order to investigate the possibility to use these compounds as EPIs. This study shows that this series of compounds potentiates nalidixic acid activity at rather low concentrations. Two hits and four pharmacophoric groups have been identified as substrates of efflux pumps. However, the affinity for the efflux target is not sufficiently higher to reverse totally the resistance to nalidixic acid. New chemical modifications are under consideration to improve the affinity to the target: a change in the position of pharmacophoric groups on the hydantoin scaffold is particularly investigated. 
Experimental
Chemistry
NMR spectra were recorded on following apparatus: a Varian Mercury VX 300 MHz PFG instrument (Varian Inc., Palo Alto, CA, USA) in [d6]-DMSO at ambient temperature using the solvent signal as an internal standard (300 MHz for 1 H and 75 MHz for 13 C) and on a Brucker ARX 200 MHz spectrometer with tetramethylsilane (TMS) as internal reference; chemical shifts are given on the d (ppm) scale with J values in Hertz. Thin-layer chromatography was performed on pre-coated Merck silica gel 60 F 254 aluminum sheets, the used solvent systems were: (I) toluene/acetone 40:3; (II) toluene/acetone/methanol 15:5:1; (III) toluene/acetone/methanol 5:5:1; (IV) methylene chloride/acetone 10:2, (V) methylene chloride/methanol 1:1. Melting points were determined using Mel-Temp II apparatus and are uncorrected. Elemental analyses were within AE0.4% of the theoretical values unless stated otherwise. Syntheses and chemical characteristics for compounds 2e8, 12e15, 30e34, 42 and 43 were described earlier [13,15e17] .
General procedure for bromoalkyl derivatives (35e40)
A mixture of the appropriate N3-substituted derivative of 5,5diphenylhydantoin 31 or 32 (30 mmol), TEBA (3.96 mmol, 0.9 g) and potassium carbonate (87 mmol, 12 g) in acetone (60 mL) was stirred under reflux for 1 h, then an appropriate dibromoalkane (36e42 mmol, 1.2e1.4 eq) in acetone (30 mL) was added. The mixture was stirred at room temperature for 45e150 h, according to a progress controlled by TLC (I). Then, inorganic precipitate was filtered off, the mother liquor was evaporated. The residue was crystallized with methanol. 
5.1.2.
General procedure for N1-substituted piperazine derivatives (16, 18e20, 41) An appropriate N1-substituted piperazine (7.5 mmol), K 2 CO 3 (3 g), TEBA (0.2 g) were suspended in acetone (15e20 ml) and stirred under reflux for 30 min. N-1-bromoalkyl-5,5diphenylhydantoin derivatives 36e40 (7.5e8.5 mmol) dissolved in acetone (20e23 ml) were added. The mixture was stirred under reflux for 3.5e8.5 h and stirring was continued at room temperature overnight. The inorganic precipitate was separated by filtration and washed with acetone (3 Â 10 ml). Combined filtrates were evaporated. Pure compounds (16, 18e20, 41) in basic form were obtained from the residue using one of the following methods: (A)crystallization with methanol; (B)-the residue was dissolved in methylene chloride (10e15 ml), washed with 1% solution of HCl (2 Â 10e15 ml) and water (2 Â 10 ml), dried with Na 2 SO 4 anhydrous, evaporated to give a new residue that was crystallized with methanol; (C)-purification using chromatography column with solvent system (IV). 
Microbiological assays
To determine minimal inhibitory concentrations (MICs), approximately 10 6 cells were inoculated into 1 mL of Muel-lereHinton broth containing two fold serial dilutions of nalidixic acid. Results were read after 18 h at 37 C. To study synergistic activity, different fixed sub-inhibitory concentrations of the potential inhibitors, determined without antibiotic, were added during incubation with nalidixic acid. In addition, the reference efflux pump inhibitor, PAbN, was used at 0.050 mM. Control experiments were carried out without the different inhibitors.
